Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients

Relation with serotonin levels

Cristiana Rossi, Luigi Alberto Pini, Maria Letizia Cupini, Paolo Calabresi, Paola Sarchielli

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background: Chronic migraine (CM) and medication-overuse headaches (MOH) are well-recognized disabling conditions affecting a significant portion of the headache population attending centers specialized in treating headaches. A dysfunctioning of the serotonergic system has been demonstrated in MOH and CM patients. Here we report on our assessment of the dysfunctioning of the endocannabinoid system as a potential underlying factor in pathogenic mechanisms involved in CM and MOH. Method: To test the hypothesis of an impairment in the endocannabinoid system in patients with MOH and CM and to assess its relationship with any disruption of the serotonergic system, we determined the levels of the two main endogenous cannabinoids, anandamide (AEA) and 2-acylglycerol (2-AG), in platelets of 20 CM patients, 20 MOH patients and 20 control subjects and also measured the platelet serotonin levels in the same patients. Results: We found that 2-AG and AEA levels were significantly lower in MOH patients and CM patients than in the control subjects, without significant differences between the two patient groups. Serotonin levels were also strongly reduced in the two patient groups and were correlated with 2-AG levels, with higher values for MOH patients. Conclusion: These data support the potential involvement of a dysfunctioning of the endocannabinoid and serotonergic systems in the pathology of CM and MOH. These systems appear to be mutually related and able to contribute to the chronification of both CM and MOH.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalEuropean Journal of Clinical Pharmacology
Volume64
Issue number1
DOIs
Publication statusPublished - Jan 2008

Fingerprint

Secondary Headache Disorders
Endocannabinoids
Migraine Disorders
Serotonin
Blood Platelets
Glycerides
Headache
Cannabinoids

Keywords

  • Chronic headache
  • Endocannabinoids
  • Medication-overuse headache
  • Serotonin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients : Relation with serotonin levels. / Rossi, Cristiana; Pini, Luigi Alberto; Cupini, Maria Letizia; Calabresi, Paolo; Sarchielli, Paola.

In: European Journal of Clinical Pharmacology, Vol. 64, No. 1, 01.2008, p. 1-8.

Research output: Contribution to journalArticle

@article{90a315a8bb57462e9abab206e46c67c7,
title = "Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: Relation with serotonin levels",
abstract = "Background: Chronic migraine (CM) and medication-overuse headaches (MOH) are well-recognized disabling conditions affecting a significant portion of the headache population attending centers specialized in treating headaches. A dysfunctioning of the serotonergic system has been demonstrated in MOH and CM patients. Here we report on our assessment of the dysfunctioning of the endocannabinoid system as a potential underlying factor in pathogenic mechanisms involved in CM and MOH. Method: To test the hypothesis of an impairment in the endocannabinoid system in patients with MOH and CM and to assess its relationship with any disruption of the serotonergic system, we determined the levels of the two main endogenous cannabinoids, anandamide (AEA) and 2-acylglycerol (2-AG), in platelets of 20 CM patients, 20 MOH patients and 20 control subjects and also measured the platelet serotonin levels in the same patients. Results: We found that 2-AG and AEA levels were significantly lower in MOH patients and CM patients than in the control subjects, without significant differences between the two patient groups. Serotonin levels were also strongly reduced in the two patient groups and were correlated with 2-AG levels, with higher values for MOH patients. Conclusion: These data support the potential involvement of a dysfunctioning of the endocannabinoid and serotonergic systems in the pathology of CM and MOH. These systems appear to be mutually related and able to contribute to the chronification of both CM and MOH.",
keywords = "Chronic headache, Endocannabinoids, Medication-overuse headache, Serotonin",
author = "Cristiana Rossi and Pini, {Luigi Alberto} and Cupini, {Maria Letizia} and Paolo Calabresi and Paola Sarchielli",
year = "2008",
month = "1",
doi = "10.1007/s00228-007-0391-4",
language = "English",
volume = "64",
pages = "1--8",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients

T2 - Relation with serotonin levels

AU - Rossi, Cristiana

AU - Pini, Luigi Alberto

AU - Cupini, Maria Letizia

AU - Calabresi, Paolo

AU - Sarchielli, Paola

PY - 2008/1

Y1 - 2008/1

N2 - Background: Chronic migraine (CM) and medication-overuse headaches (MOH) are well-recognized disabling conditions affecting a significant portion of the headache population attending centers specialized in treating headaches. A dysfunctioning of the serotonergic system has been demonstrated in MOH and CM patients. Here we report on our assessment of the dysfunctioning of the endocannabinoid system as a potential underlying factor in pathogenic mechanisms involved in CM and MOH. Method: To test the hypothesis of an impairment in the endocannabinoid system in patients with MOH and CM and to assess its relationship with any disruption of the serotonergic system, we determined the levels of the two main endogenous cannabinoids, anandamide (AEA) and 2-acylglycerol (2-AG), in platelets of 20 CM patients, 20 MOH patients and 20 control subjects and also measured the platelet serotonin levels in the same patients. Results: We found that 2-AG and AEA levels were significantly lower in MOH patients and CM patients than in the control subjects, without significant differences between the two patient groups. Serotonin levels were also strongly reduced in the two patient groups and were correlated with 2-AG levels, with higher values for MOH patients. Conclusion: These data support the potential involvement of a dysfunctioning of the endocannabinoid and serotonergic systems in the pathology of CM and MOH. These systems appear to be mutually related and able to contribute to the chronification of both CM and MOH.

AB - Background: Chronic migraine (CM) and medication-overuse headaches (MOH) are well-recognized disabling conditions affecting a significant portion of the headache population attending centers specialized in treating headaches. A dysfunctioning of the serotonergic system has been demonstrated in MOH and CM patients. Here we report on our assessment of the dysfunctioning of the endocannabinoid system as a potential underlying factor in pathogenic mechanisms involved in CM and MOH. Method: To test the hypothesis of an impairment in the endocannabinoid system in patients with MOH and CM and to assess its relationship with any disruption of the serotonergic system, we determined the levels of the two main endogenous cannabinoids, anandamide (AEA) and 2-acylglycerol (2-AG), in platelets of 20 CM patients, 20 MOH patients and 20 control subjects and also measured the platelet serotonin levels in the same patients. Results: We found that 2-AG and AEA levels were significantly lower in MOH patients and CM patients than in the control subjects, without significant differences between the two patient groups. Serotonin levels were also strongly reduced in the two patient groups and were correlated with 2-AG levels, with higher values for MOH patients. Conclusion: These data support the potential involvement of a dysfunctioning of the endocannabinoid and serotonergic systems in the pathology of CM and MOH. These systems appear to be mutually related and able to contribute to the chronification of both CM and MOH.

KW - Chronic headache

KW - Endocannabinoids

KW - Medication-overuse headache

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=38049012986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049012986&partnerID=8YFLogxK

U2 - 10.1007/s00228-007-0391-4

DO - 10.1007/s00228-007-0391-4

M3 - Article

VL - 64

SP - 1

EP - 8

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 1

ER -